BridgeBio Pharma, Inc. (BBIO) Q4 2025 Earnings Call Transcript

Operator

Good afternoon. I’ll be your conference operator today. [Operator Instructions] Before we begin, I’d like to remind everyone that today’s call may contain forward-looking statements within the meaning of the federal securities laws, including, but not limited to, statements about BridgeBio’s future operating and financial performance, business plans and prospects and strategy.

These statements are based on current expectations and assumptions that are subject to risks and uncertainties, which could cause actual results to differ materially from those expressed or implied in these forward-looking statements. For a discussion of these risks and uncertainties, please refer to the disclosure in today’s earnings release and BridgeBio’s periodic reports and SEC filings.

All statements made here are based on information available to BridgeBio as of today, and the company undertakes no obligation to update any forward-looking statements made during this call, except as required by law. With that completed, BridgeBio, you may begin your conference.

Chinmay Shukla
Senior Vice President of Strategic Finance

Good afternoon, everyone, and thank you for joining BridgeBio Pharma’s Fourth Quarter 2025 Earnings Call. My name is Chinmay Shukla. I’m the Senior Vice President of Strategic Finance at BridgeBio. With me today are Neil Kumar, our CEO, who will provide opening remarks and discuss overall corporate performance; Matt Outten, our Chief Commercial Officer, who will provide more details about